Phase II trial of amrubicin treatment as palliative-intended chemotherapy for previously treated malignant pleural mesothelioma
Latest Information Update: 29 Mar 2019
At a glance
- Drugs Amrubicin (Primary)
- Indications Malignant-mesothelioma
- Focus Therapeutic Use
- 22 Mar 2019 Planned End Date changed from 31 May 2020 to 31 Mar 2019.
- 22 Mar 2019 Status changed from recruiting to discontinued.
- 20 May 2018 Planned End Date changed from 31 May 2018 to 31 May 2020.